Gao Hongying, Sun Xiuyun, Rao Yu
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, P.R. China.
Tsinghua University-Peking University Joint Center for Life Sciences, Beijing 100084, P.R. China.
ACS Med Chem Lett. 2020 Mar 12;11(3):237-240. doi: 10.1021/acsmedchemlett.9b00597.
PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer Ingelheim, etc.), and biotechnology companies. PROTACs opened a new chapter for novel drug development. However, any new technology will face many new problems and challenges. Perspectives on the potential opportunities and challenges of PROTACs will contribute to the research and development of new protein degradation drugs and degrader tools.
PROTAC诱导的靶向蛋白降解已成为药物开发中的一种新型治疗策略，并受到学术机构、大型制药企业（如阿斯利康、拜耳、诺华、安进、辉瑞、葛兰素史克、默克和勃林格殷格翰等）以及生物技术公司的青睐。PROTAC为新型药物开发开启了新篇章。然而，任何新技术都会面临许多新问题和挑战。对PROTAC潜在机遇和挑战的展望将有助于新型蛋白降解药物和降解剂工具的研发。
